viewPharmaxis Ltd

Pharmaxis expects an FDA decision on Bronchitol mid-year after positive committee recommendation

Pharmaxis Ltd (ASX:PXS) chief executive officer Gary Phillips updates Proactive Investors on the positive recommendation received from a US Food and Drug Administration advisory committee for the use of its inhaled powder Bronchitol in adult patients with cystic fibrosis. 
Phillips says the US is the last major territory where Bronchitol has not yet been approved and the company expects an FDA decision mid-year.
Clinical trials have shown Bronchitol improves lung function in CF patients.
It is delivered by a portable inhaler, allowing patients to fit in taking medication with their daily lives.


Quick facts: Pharmaxis Ltd

Price: 0.2 AUD

Market: ASX
Market Cap: $78.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...



Pharmaxis hopeful of FDA approval for cystic fibrosis inhalation medicine...

Pharmaxis Ltd (ASX:PXS) chief executive officer Gary Phillips updates Proactive Investors on the FDA approval timeframe for the company’s Bronchitol inhalation medicine used to treat adult cystic fibrosis patients. The healthcare-focused company is confident it will meet information...

on 13/8/19

2 min read